Ischemic Stroke and Systemic Embolism Among One-and-Done Direct Oral Anticoagulant Users with Non-valvular Atrial Fibrillation

Figures

• 

  Fig. 1. Study design. DOAC direct oral anticoagulant, SE systemic embolism

• 

  Fig. 2. Identification of NVAF population. AF atrial fibrillation, DOAC direct oral anticoagulant, NVAF non-valvular atrial fibrillation. *Patients were excluded from the study population if they had (1) ≥ 1 claim with any of the following diagnoses or procedures at baseline: mitral stenosis, mechanical heart-valve, venous thromboembolism, hip or knee replacement surgery, organ or tissue replaced by transplant; (2) pregnancy during or after the baseline period; (3) ≥ 1 claim with a diagnosis of stroke (ischemic or hemorrhagic) or systemic embolism during an inpatient admission on the index date or within 30 days prior to the index date; (4) > 1 claim for DOACs (i.e., apixaban, betrixaban, dabigatran, edoxaban, rivaroxaban) on the index date; or (5) > 1 final claim status (e.g., approved and abandoned) for the index DOAC on the index date. †Patients were excluded during the landmark period if they had (1) ≤ 90 days of clinical activity post-index; (2) stroke or systemic embolism diagnosis in an inpatient setting within the first 90 days post-index (i.e., during landmark period); or (3) > 30 days of supply on the index DOAC claim

• 

  Fig. 3. Ischemic stroke or SE probability in weighted one-and-done versus continuer cohorts. CI confidence interval, DOAC direct oral anticoagulant, SE systemic embolism. Ischemic stroke and SE events were identified in an inpatient setting. The time to the first event was measured from day 91 post-index date (i.e., first day after the end of the landmark period); patients for whom the event was not observed during the follow-up period were censored at the end of the follow-up period. †p < 0.05

• 

  Fig. 4. Risk of ischemic stroke and SE in weighted one-and-done versus continuer cohorts. HR hazard ratio, CI confidence interval, SE systemic embolism. Ischemic stroke and SE were identified in an inpatient setting. HRs were generated using univariate weighted Cox proportional hazard models. †p < 0.05

• 

  Fig. 5. Ischemic stroke or SE probability in weighted one-and-done versus continuer cohorts (75-day landmark period). CI confidence interval, DOAC direct oral anticoagulant, SE systemic embolism. Ischemic stroke and SE events were identified in an inpatient setting. The time to the first event was measured from day 76 post-index date (i.e., first day after the end of the landmark period); patients for whom the event was not observed during the follow-up period were censored at the end of the follow-up period. †p < 0.05

• 

  Fig. 6. Risk of ischemic stroke or SE in weighted one-and-done versus continuer cohorts (75-day landmark period). HR hazard ratio, CI confidence interval, SE systemic embolism. Ischemic stroke and SE were identified in an inpatient setting. HRs were generated using univariate weighted Cox proportional hazard models. †p < 0.05